Therapeutic efficacy and safety of plasmapheresis in elderly patients with neuromyelitis optica spectrum disorder: a single-center observational study

被引:3
|
作者
Zhang, Weihe [1 ]
Jiao, Yujuan [2 ]
Cui, Lei [2 ]
Zhang, Yeqiong [2 ]
Jiao, Jinsong [2 ]
Jin, Ming [3 ]
Yuan, Wei [3 ]
You, Yang [4 ]
Wang, Renbin [2 ]
Peng, Dantao [1 ]
机构
[1] China Japan Friendship Hosp, Dept Neurol, 2 Yinghua, Beijing 100029, Peoples R China
[2] China Japan Friendship Hosp, Dept Neurol, Beijing, Peoples R China
[3] China Japan Friendship Hosp, Dept Ophthalmol, Beijing, Peoples R China
[4] 964 Hosp Peoples Liberat Army, Dept Neurol, Changchun, Peoples R China
关键词
efficacy; elderly; neuromyelitis optica spectrum disorder; plasma exchange; safety; PLASMA-EXCHANGE; DIAGNOSTIC-CRITERIA; OUTCOMES; MARKER; ATTACK; AGE;
D O I
10.1177/17562864231162420
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background:Neuromyelitis optica spectrum disorder (NMOSD) is a devastating autoimmune disorder with cycles of escalating relapse. Rates of diagnosis in the elderly are increasing. Therapeutic decision-making is more challenging in elderly patients due to multiple comorbidities and high risk of drug-induced side effects. Objective:This retrospective study assessed the efficacy and safety of standard plasma exchange (PLEX) treatment in an elderly population with NMOSD. Design:Seventy-six patients with NMOSD who received PLEX were apportioned to two groups as either elderly (> 60 years, n = 26) or young (<60 years) at the time of the first procedure. Methods:Therapeutic response was judged according to functional recovery at 6 months, as reflected by Expanded Disability Status Scale (EDSS) and visual outcome scale (VOS) scores. Results:The mean age of the 26 elderly patients was 67.7 +/- 7.9 years (range 60-87 years); the population was predominantly female (88.5%). PLEX sessions were generally well tolerated among the elderly. Compared with the young patients, the elderly had significantly more comorbidities and concomitant medications. Twenty-four (96.0%) elderly patients showed functional improvement at 6 months after PLEX, of which 15 (60.0%) experienced moderate-to-marked improvement. Six months after the initial PLEX treatment, the patients overall experienced a significant improvement in EDSS and VOS scores. Logistic regression showed that severe optic neuritis attack was a significant independent prognostic factor associated with poor PLEX response. The groups were comparable regarding overall or serious adverse events. The rate of transient hypotension was significantly higher in the elderly compared with the young. Conclusion:PLEX is an effective and safe therapy for elderly patients with NMOSD and should be considered a treatment option during NMOSD attacks. In the elderly, preventive measures against hypotension are recommended before PLEX.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Clinical Efficacy of Plasmapheresis in Patients with Neuromyelitis Optica Spectrum Disorder and Effects on Circulating Anti-Aquaporin-4 Antibody Levels
    Kim, Su-Hyun
    Kim, Woojun
    Huh, So-Young
    Lee, Kyue Yim
    Jung, In Ja
    Kim, Ho Jin
    JOURNAL OF CLINICAL NEUROLOGY, 2013, 9 (01): : 36 - 42
  • [32] Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders
    Novi, Giovanni
    Bovis, Francesca
    Capobianco, Marco
    Frau, Jessica
    Mataluni, Giorgia
    Curti, Erica
    Zuliani, Luigi
    Cavalla, Paola
    Brambilla, Laura
    Annovazzi, Pietro
    Repice, Anna Maria
    Lanzillo, Roberta
    Esposito, Sabrina
    Benedetti, Luana
    Maietta, Ilaria
    Sica, Francesco
    Buttari, Fabio
    Malucchi, Simona
    Fenu, Giuseppe
    Landi, Doriana
    Bosa, Chiara
    Realmuto, Sabrina
    Malentacchi, Maria
    Granella, Franco
    Signori, Alessio
    Bonavita, Simona
    Uccelli, Antonio
    Sormani, Maria Pia
    Nozzolillo, Agostino
    Gallo, Fabio
    Signoriello, Elisabetta
    Clerici, Valentina Torri
    La Gioia, Sara
    Cocco, Eleonora
    Sartori, Arianna
    Rasia, Sarah
    Cordioli, Cinzia
    Barone, Stefania
    Solaro, Claudio
    Nociti, Viviana
    Gobbi, Claudio
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 36
  • [33] The Efficacy and Tolerability of Azathioprine for Patients with Neuromyelitis Optica Spectrum Disorder: A Systematic Review
    Espiritu, Adrian
    Pasco, Paul Matthew
    NEUROLOGY, 2019, 92 (15)
  • [34] Efficacy and safety of modified reduced-dose rituximab in Chinese patients with neuromyelitis optica spectrum disorder: A retrospective cohort study
    Cao, Shugang
    Yu, Hai
    Tian, Jingluan
    Li, Yuanyuan
    Shen, Yueping
    Ji, Xiaopei
    Wang, Xiaoyuan
    Zhou, Xiaoling
    Gu, Yanzheng
    Zhu, Feng
    Duan, Xiaoyu
    Xiao, Xinyi
    Fang, Qi
    Chen, Xiangjun
    Xue, Qun
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429
  • [35] Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study
    Ilya Ayzenberg
    Joanna Schöllhammer
    Robert Hoepner
    Kerstin Hellwig
    Marius Ringelstein
    Orhan Aktas
    Tania Kümpfel
    Markus Krumbholz
    Corinna Trebst
    Friedemann Paul
    Florence Pache
    Mark Obermann
    Lena Zeltner
    Matthias Schwab
    Achim Berthele
    Sven Jarius
    Ingo Kleiter
    Journal of Neurology, 2016, 263 : 575 - 582
  • [36] Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study
    Ayzenberg, Ilya
    Schoellhammer, Joanna
    Hoepner, Robert
    Hellwig, Kerstin
    Ringelstein, Marius
    Aktas, Orhan
    Kuempfel, Tania
    Krumbholz, Markus
    Trebst, Corinna
    Paul, Friedemann
    Pache, Florence
    Obermann, Mark
    Zeltner, Lena
    Schwab, Matthias
    Berthele, Achim
    Jarius, Sven
    Kleiter, Ingo
    JOURNAL OF NEUROLOGY, 2016, 263 (03) : 575 - 582
  • [37] Rituximab treatment in patients affected by neuromyelitis optica spectrum of disorder: long term safety and efficacy in clinical practice
    Radaelli, M.
    Moiola, L.
    Rodegher, M.
    Colombo, B.
    Barcella, V.
    Sangalli, F.
    Ferre, L.
    Fazio, R.
    Esposito, F.
    Martinelli, V.
    Comi, G.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 88 - 88
  • [38] Efficacy and safety of eculizumab in patients with neuromyelitis optica spectrum disorder previously treated with rituximab: findings from PREVENT
    Levy, M.
    Berthele, A.
    Kim, H. J.
    Fujihara, K.
    Nakashima, I.
    Oreja-Guevara, C.
    Palace, J.
    Pittock, S.
    Terzi, M.
    Totolyan, N.
    Viswanathan, S.
    Wang, K. -C.
    Pace, A.
    Yountz, M.
    Lawson, D.
    Laudon-Meyer, E.
    Wingerchuk, D.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 1 - 2
  • [39] Efficacy and safety of rehabilitation exercise in neuromyelitis optica spectrum disorder during the acute phase: A prospective cohort study
    Li, Qinying
    Wang, Bei
    Cheng, Bingyuan
    Liu, Chi
    Li, Nan
    Dai, Guifeng
    Xiao, Han
    Zhou, Lei
    ZhangBao, Jingzi
    Wang, Liang
    Zhao, Chongbo
    Lu, Jiahong
    Quan, Chao
    Li, Fang
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 61
  • [40] Effectiveness of rituximab versus oral immunosuppressive therapies in neuromyelitis optica spectrum disorder in a racially diverse cohort of subjects: A single-center retrospective study
    Dresser, Laura
    Chaar, Widad Abou
    Reder, Anthony T.
    Abuaf, Amanda Frisosky
    Cipriani, Veronica P.
    Javed, Adil
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 74